Free Newsletter
Illumina: Cheap DNA mapping will become routine
Illumina CEO Jay Flatley says that in five years we'll have the kind of affordable technology needed to map every child's DNA at birth. And in 10 years, Flatley predicted in an interview with The Times, the service will become a routine offering.
Armed with that information, a doctor would be able to get an accurate idea of a person's risk for disease, allowing them to suggest preventive methods to avoid disease as well as early screening to detect high-risk conditions at an early stage.
Illumina, which plans to offer whole-genome sequencing within two years for as little as $10,000, adds that soon the only barriers to DNA mapping will be fear that insurers or employers could get a copy of your DNA and use the information against you. That in turn will prompt governments to pass new laws, much like the U.S. has already done, to guard against the misuse of a person's genetic profile.
"The limitations are sociological; when and where people think it can be applied, the concerns people have about misinformation and the background ethics questions," says Flatley. In just four years, says Flatley, DNA mapping will cost less than $1,000.
- read the story in The Times
Related Articles:
Illumina deal highlights hunt for sub-$1,000 sequencing
Illumina snares sequencing tech in $60M buyout
Illumina focuses on molecular diagnostics
Four companies lead genome sequencing race
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: